Metadata record for the manuscript: Molecular landscape and efficacy of HER2-targeted therapy in patients with HER2-mutated metastatic breast cancer

Summary This metadata record provides details of the data supporting the claims of the related manuscript: “Molecular landscape and efficacy of HER2-targeted therapy in patients with HER2-mutated metastatic breast cancer”. The related study investigated the effect of HER2 mutations on the likelihood of a response to HER2-targeted therapies in patients stratified according to their HER2 amplification status, under the hypothesis that this might help clinicians choose more precise HER2-targeted therapies. Data access The genome sequence data have been deposited in China National GeneBank DataBase (CNGBdb): https://db.cngb.org/search/project/CNP0001305/. The file “Supplementary Data 1.xlsx” lists somatic mutations identified in 1184 patients, and is available together with this metadata record. The files “Clinical data20200728.xlsx” and “Patient therapy responses and adverse events data.xlsx” contain data on the patients—these datasets are not publicly available in order to protect patient privacy, and dataset requests should be sent to Dr Ma; contact details below: Dr Fei MaNational Cancer Center/ National Clinical Research Center for Cancer/ Cancer Hospital，Chinese Academy of Medical Sciences and Peking Union Medical CollegeMedical OncologyNo. 17 Panjiayuan Nanli, Beijing, 100021, ChinaBeijing, [e-mail] Name of Institutional Review Board or ethics committee that approved the studyRegulatory and Ethics Committees of National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (ref: 16-038/1117 and 17-180/1436). Clinical trial registry URLhttps://clinicaltrials.gov/ct2/show/NCT03412383?cond=NCT03412383&draw=2&rank=1